Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (4312)	5/16/1998 5:39:00 PM
From: Steve Fancy	of 6136

Article in Barrons... Life Support Promising cancer therapies raise hope for beleaguered biotechs interactive.wsj.com Sounds like competition in the cancer drug arena is going to be fierce. Here's what they said regarding AGPH: Its newfound pizzazz notwithstanding, EntreMed isn't alone in plumbing the mysteries of angiogenesis. British Biotech and Agouron already are in clinical trials with metal-binding proteinase inhibitors, drugs that curb the enzyme activity that promotes blood-vessel formation and the migration of tumor cells. La Jolla, California-based Agouron, in fact, has a number of welcome distinctions: a successful first product, Viracept, for treatment of the AIDS virus, and modest earnings to prove it. The company moved into the black in this year's fiscal first quarter (ended September), and by Butler's reckoning could net 91 cents for the year and $1.40 in fiscal '99. But the shares, at 34 7/8, are down from a high of 56 1/2, on investor fears that a second commercial product could be a long time in coming.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next